Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Date:7/31/2014

SAN FRANCISCO, July 31, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2014.

Cash and investments in marketable securities at June 30, 2014 were $301.4 million as compared to $309.1 million at March 31, 2014."The second half of 2014 will be an exciting time for Nektar as we look forward to significant milestones for a number of our late-stage clinical programs," said Howard W. Robin, President and Chief Executive Officer of Nektar. "The first of these is the potential US and EU approvals of Movantik™ with our partner AstraZeneca. If approved, Movantik would be the first oral targeted therapy approved for opioid induced constipation, a debilitating condition that occurs in up to 80%* of the 69 million chronic pain patients worldwide. Our partner Baxter has completed dosing in their Phase 3 study for BAX 855, a longer-acting PEGylated Factor VIII therapy to treat hemophilia A and plans to file the BLA in the U.S. by the end of this year. In our proprietary pipeline, we are on track for topline results from the Phase 3 breast cancer study for NKTR-102 in Q1 2015."

Revenue in the second quarter of 2014 was $28.5 million as compared to $33.9 million in the second quarter of 2013. Year-to-date revenue for 2014 was $48.3 million as compared to $56.9 million in the first half of 2013.  The decrease in revenue in the second quarter and first half of 2014 as compared to the same periods in 2013 is primarily due to decreased manufacturing activity.  Revenue included non-cash royalty revenue, related to our 2012 royalty monetization, of $4.8 million and $10.6 million in the second quarter and first half of 2014, respectively, and $3.8 million and $8.2 million in the second quarter and first half of 2013, respectively. This non-cash royalty revenue is offset by non-cash interest exp
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
7. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... BEIJING , Aug. 4, 2015 Concord Medical ... a leading specialty hospital management solution provider and operator of ... China , today announced it will release ... the market closes on August 17, 2015. Management ... following day, at 8:00 a.m. EDT on August 18, 2015 ...
(Date:8/4/2015)... SAN DIEGO , Aug. 4, 2015 /PRNewswire/ ... a three-dimensional biology company focused on delivering scientific ... announced that the Company has hired Paul ... in vitro tissue service and product business. Mr. Gallant ... R&D experience in the drug discovery industry, most ...
(Date:8/4/2015)... 4, 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: ... development and commercialization of targeted antiviral therapies, today ... will present live at VirtualInvestorConferences.com on August 6, ... TIME: 12:15PM EDT LINK: http://tinyurl.com/aug6-pre-ctrv ... online event where investors are invited to ask ...
Breaking Medicine Technology:Concord Medical to Report Second Quarter 2015 Financial Results on August 17, 2015 2Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 2Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 3ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 3
... , May 10 Ferring Pharmaceuticals ... Women,s Health product portfolio with the acquisition of ... acid), a first-in-class, non-hormonal therapy indicated specifically for ... (HMB).  The company will initially market LYSTEDA in ...
... 10 Ampio Pharmaceuticals, Inc. (OTC Bulletin Board: AMPE), today announced the ... Mr. Macaluso replaces Dr. David Bar-Or, who remains the Chief Scientific Officer and ... Bar-Or have served on Ampio,s Board since the date of its acquisition of ... , , ...
Cached Medicine Technology:Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc. 2Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc. 3Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc. 4Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc. 5Ampio Pharmaceuticals, Inc. Appoints New Chairman and Chief Financial Officer 2
(Date:8/4/2015)... ... 04, 2015 , ... assistPoint Partners, LLC is proud ... patient assistance programs. Through a secure web portal, assistPoint connects Life Sciences, Patients ... level, cloud-based application and workflow solution. This provides cancer center patient advocates, financial ...
(Date:8/4/2015)... FL (PRWEB) , ... August 04, 2015 , ... ... testing organization which provides vascular, electrocardiogram (EKG), echocardiogram, and NCV testing, announced their ... has been successfully identifying previously undiagnosed cardiovascular abnormalities one program at a time. ...
(Date:8/4/2015)... ... August 04, 2015 , ... Bayco Products, Inc. announces ... to fit, for example, on hard hats that have a flip-up face shield. The ... allows users to work without having to remove their headlamp when raising or lowering ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... Worldwide Power Products is expanding its reach in Texas. Effective July 1st of ... Systems North Texas generator division. With the North Texas acquisition, Worldwide Power ...
(Date:8/4/2015)... , ... August 04, 2015 , ... One of the ... to discuss his new book, The Pain Antidote , which provides strategies for ... Las Vegas Recovery Center’s Chronic Pain Treatment Program, wrote the book in conjunction with ...
Breaking Medicine News(10 mins):Health News:assistPoint.com Web Site Launched 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 3Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 3Health News:North Texas Acquisition Press Release 2Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 2Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 3
... hospitals , , MONDAY, Dec. 17 (HealthDay News) -- A ... and anxiety that often follows major surgery, new research ... was equivalent to a [dose] of morphine, which was ... Hinshaw, professor of surgery and a member of the ...
... NEW MARTINSVILLE, W.Va., Dec. 17 In ... become tomorrow,s environmental,stewards, Bayer Corporation and the ... (UNEP RONA) today announced a new World,Environment ... Competition in Bayer MaterialScience New Martinsville partner,schools., ...
... OWINGS MILLS, Md., Dec. 17 Medifast, Inc.,(NYSE: ... has received approval to sell,Medifast Weight Control Centers ... available in 43 states. Medifast recently,received approval to ... Rhode Island and Virginia., "The Medifast Weight ...
... season is a,great opportunity to relax, spend time with family, ... the next 12 months. These top resolutions,offered by the American ... healthy new you in 2008., "Creating and sticking to ... you can give yourself this holiday season," said AMA,President, Ron ...
... a high volume of corrective surgeries show higher survival ... -- Babies with congenital heart defects are more likely ... the most experience in treating such cases, U.S. researchers ... figures from the 2003 Kids, Inpatient Database, which is ...
... Murtha, Chairman of the House Appropriations Subcommittee on Defense, this ... veterans blinded by war and for research to restore their ... gives the Man of Vision Award to an individual who ... of the challenges of vision loss. Among previous awardees have ...
Cached Medicine News:Health News:Massage Eases Pain, Anxiety After Surgery 2Health News:New Bayer, United Nations Partnership Brings International Environment and Art Competition to Local Elementary and Middle Schools 2Health News:New Bayer, United Nations Partnership Brings International Environment and Art Competition to Local Elementary and Middle Schools 3Health News:New Bayer, United Nations Partnership Brings International Environment and Art Competition to Local Elementary and Middle Schools 4Health News:Medifast, Inc. Receives Approval to Sell Medifast Weight Control Centers Franchises in Seven Additional States 2Health News:AMA: Resolutions for a Healthy New You in the New Year 2Health News:Babies With Heart Defects Do Best at Hospitals With Most Experience 2Health News:Champion of blinded soldiers, Congressman Murtha, is Man of Vision 2
... Sutureless Mitek ConTack Labral Anchor is ... washer used for soft tissue reattachment ... adjusts to the bony contour of ... anchor uses Radial Osteo Compression (ROC) ...
... Suture Anchors just got better. How can ... do that? Simply by becoming more convenient ... mini-open, and arthroscopic. The TwinFix Suture Anchor ... with a unique, convenient and timesaving anchor ...
... EZ fasteners are polyethylene ... tissue reattachment to bone. ... radial osteo compression (ROC) ... strength. ROC EZ fasteners ...
The Knotless Anchor, a titanium alloy implant, is used for soft tissue reattachment to bone. The Knotless Anchor is indicated for open and arthroscopic Bankart repairs....
Medicine Products: